The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. ⋯ LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).